Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

a Clinical Trial Phase II Prospective, Single-arm Study of Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced Non-small Cell Lung Cancer

NCT05448781 is registered in ClinicalTrials.gov with Affiliated Cancer Hospital & Institute of Guangzhou Medical University as lead sponsor.

NCT NCT05448781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05448781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
a Clinical Trial Phase II Prospective, Single-arm Study of Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced Non-small Cell Lung Cancer
Lead sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
July 20, 2022
Completion date
December 20, 2023
Enrollment
38 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endostatin, non small cell lung cancer